Stephen C. Mack

Stephen C. Mack

Auto-generated profile, based on publicly available information

Stephen C. Mack

Department of Pediatric Hematology and Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA; Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2015 in Genes & Development
Verified
Journal Article
Open access
PDF file
JLJustin Lathia
Justin Lathia
SMStephen C. Mack
Stephen C. Mack
EMErin Mulkearns-Hubert
Erin Mulkearns-Hubert
CVClaudia L.L. Valentim
Claudia L.L. Valentim
JRJeremy N. Rich
Jeremy N. Rich
Tissues with defined cellular hierarchies in development and homeostasis give rise to tumors with cellular hierarchies, suggesting that tumors recapitulate specific tissues and mimic their origins. Glioblastoma (GBM) is the most prevalent and malignant primary brain tumor and contains self-renewing, tumorigenic cancer stem cells (CSCs) that contribute to tumor initiation and therapeutic resistance. As normal stem and progenitor cells participate in tissue development and repair, these developmental programs re-emerge in CSCs to support the development and progressive growth of tumors. Elucidation of the molecular mechanisms that govern CSCs has informed the development of novel targeted therapeutics for GBM and other brain cancers. CSCs are not self-autonomous units; rather, they function within an ecological system, both actively remodeling the microenvironment and receiving critical maintenance cues from their niches. To fulfill the future goal of developing novel therapies to collapse CSC dynamics, drawing parallels to other normal and pathological states that are highly interactive with their microenvironments and that use developmental signaling pathways will be beneficial.

10 April 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PNPaul A. Northcott
Paul A. Northcott
Andrey KorshunovAndrey Korshunov
Andrey Korshunov
HWHendrik Witt
Hendrik Witt
THThomas Hielscher
Thomas Hielscher
CECharles G. Eberhart
Charles G. Eberhart
MTMichael D. Taylor
Michael D. Taylor
Purpose: Recent genomic approaches have suggested the existence of multiple distinct subtypes of medulloblastoma. We studied a large cohort of medulloblastomas to determine how many subgroups of the disease exist, how they differ, and the extent of overlap between subgroups.Methods: We determined gene expression profiles and DNA copy number aberrations for 103 primary medulloblastomas. Bioinformatic tools were used for class discovery of medulloblastoma subgroups based on the most informative genes in the data set. Immunohistochemistry for subgroup-specific signature genes was used to determine subgroup affiliation for 294 nonoverlapping medulloblastomas on two independent tissue microarrays.Results: Multiple unsupervised analyses of transcriptional profiles identified the following four distinct, nonoverlapping molecular variants: WNT, SHH, group C, and group D. Supervised analysis of these four subgroups revealed significant subgroup-specific demographics, histology, metastatic status, and DNA copy number aberrations. Immunohistochemistry for DKK1 (WNT), SFRP1 (SHH), NPR3 (group C), and KCNA1 (group D) could reliably and uniquely classify formalin-fixed medulloblastomas in approximately 98% of patients. Group C patients (NPR3-positive tumors) exhibited a significantly diminished progression-free and overall survival irrespective of their metastatic status.Conclusion: Our integrative genomics approach to a large cohort of medulloblastomas has identified four disparate subgroups with distinct demographics, clinical presentation, transcriptional profiles, genetic abnormalities, and clinical outcome. Medulloblastomas can be reliably assigned to subgroups through immunohistochemistry, thereby making medulloblastoma subclassification widely available. Future research on medulloblastoma and the development of clinical trials should take into consideration these four distinct types of medulloblastoma.

1 May 2015 in Cancer Cell
Verified
Journal Article
Closed access
Kristian W. PajtlerKristian W. Pajtler
Kristian W. Pajtler
HWHendrik Witt
Hendrik Witt
MSMartin Sill
Martin Sill
DJDavid T.W. Jones
David T.W. Jones
VHVolker Hovestadt
Volker Hovestadt
Stefan PfisterStefan Pfister
Stefan Pfister

25 July 2012 in Nature
Verified
Journal Article
Open access
PDF file
PNPaul A. Northcott
Paul A. Northcott
DSDavid J. H. Shih
David J. H. Shih
JPJohn Peacock
John Peacock
LGLivia Garzia
Livia Garzia
AMA. Sorana Morrissy
A. Sorana Morrissy
MTMichael D. Taylor
Michael D. Taylor
Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, with at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique medulloblastomas. SCNAs are common in medulloblastoma, and are predominantly subgroup-enriched. The most common region of focal copy number gain is a tandem duplication of SNCAIP, a gene associated with Parkinson’s disease, which is exquisitely restricted to Group 4α. Recurrent translocations of PVT1, including PVT1-MYC and PVT1-NDRG1, that arise through chromothripsis are restricted to Group 3. Numerous targetable SCNAs, including recurrent events targeting TGF-β signalling in Group 3, and NF-κB signalling in Group 4, suggest future avenues for rational, targeted therapy.

14 April 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CHChristopher G. Hubert
Christopher G. Hubert
MRMaricruz Rivera
Maricruz Rivera
LSLisa C. Spangler
Lisa C. Spangler
QWQiulian Wu
Qiulian Wu
SMStephen C. Mack
Stephen C. Mack
JRJeremy N. Rich
Jeremy N. Rich
Many cancers feature cellular hierarchies that are driven by tumor-initiating cancer stem cells (CSC) and rely on complex interactions with the tumor microenvironment. Standard cell culture conditions fail to recapitulate the original tumor architecture or microenvironmental gradients and are not designed to retain the cellular heterogeneity of parental tumors. Here, we describe a three-dimensional culture system that supports the long-term growth and expansion of tumor organoids derived directly from glioblastoma specimens, including patient-derived primary cultures, xenografts, genetically engineered glioma models, or patient samples. Organoids derived from multiple regions of patient tumors retain selective tumorigenic potential. Furthermore, organoids could be established directly from brain metastases not typically amenable to in vitro culture. Once formed, tumor organoids grew for months and displayed regional heterogeneity with a rapidly dividing outer region of SOX2+, OLIG2+, and TLX+ cells surrounding a hypoxic core of primarily non-stem senescent cells and diffuse, quiescent CSCs. Notably, non-stem cells within organoids were sensitive to radiotherapy, whereas adjacent CSCs were radioresistant. Orthotopic transplantation of patient-derived organoids resulted in tumors displaying histologic features, including single-cell invasiveness, that were more representative of the parental tumor compared with those formed from patient-derived sphere cultures. In conclusion, we present a new ex vivo model in which phenotypically diverse stem and non-stem glioblastoma cell populations can be simultaneously cultured to explore new facets of microenvironmental influences and CSC biology. Cancer Res; 76(8); 2465–77. ©2016 AACR.

19 February 2014 in Nature
Verified
Journal Article
Closed access
PDF file
SMS. C. Mack
S. C. Mack
HWH. Witt
H. Witt
RPRosario M. Piro
Rosario M. Piro
LGL. Gu
L. Gu
SZS. Zuyderduyn
S. Zuyderduyn
MTM. D. Taylor
M. D. Taylor